Dr. Lulu Jiang is a Research Assistant Professor in the Pharmacology & Experimental Therapeutics department at the Chobanian and Avedisian School of Medicine. Dr. Jiang’s PhD training was from the National Institute of Environmental Health Sciences (NIEHS) in USA and MD training from Shandong University in China. She was a Postdoc Fellow in the Laboratory of Neurodegeneration mentored by Dr. Benjamin Wolozin. Her previous work demonstrated that propagated tau oligomers (but not tau fibrils) induce pathological changes in RNA metabolism and neurodegeneration. Upon that, Dr. Jiang developed an optogenetic system for controlling tau aggregation, which brought in a seminal discovery that tau oligomerization drives the accumulation of RNA binding protein HNRNPA2B1 and N6-methyladenosine modified transcripts in the aggregated tau complex. Dr. Jiang has also lead on the generation of human 3D iPSC M/AstAD based models of AD for the exploration of molecular mechanism and drug screening. Her research interests include: 1) Protein-Protein and Protein-RNA interactions in AD and related dementia; 2) Molecular mechanism of Tau prion-like propagation in Braak stages of AD; 3) Neuron-glia interactions in pathogenesis of AD and PD; 4) iPSC-induced 3D brain organoid models of neurodegenerative diseases and precision medicine; 5) Development of novel therapeutics for neurodegenerative diseases.
Postdoctoral Associate (previously held)
Boston University Chobanian & Avedisian School of Medicine
Pharmacology & Experimental Therapeutics
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 14 results.
Rickner HD, Jiang L, Hong R, O'Neill NK, Mojica CA, Snyder BJ, Zhang L, Shaw D, Medalla M, Wolozin B, Cheng CS. Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. Nat Commun. 2022 Oct 21; 13(1):6275. PMID: 36271092; PMCID: PMC9587045; DOI: 10.1038/s41467-022-34005-1;
Jiang L, Lin W, Zhang C, Ash PEA, Verma M, Kwan J, van Vliet E, Yang Z, Cruz AL, Boudeau S, Maziuk BF, Lei S, Song J, Alvarez VE, Hovde S, Abisambra JF, Kuo MH, Kanaan N, Murray ME, Crary JF, Zhao J, Cheng JX, Petrucelli L, Li H, Emili A, Wolozin B. Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Mol Cell. 2021 10 21; 81(20):4209-4227.e12.View Related Profiles. PMID: 34453888; PMCID: PMC8541906; DOI: 10.1016/j.molcel.2021.07.038;
Ash PEA, Lei S, Shattuck J, Boudeau S, Carlomagno Y, Medalla M, Mashimo BL, Socorro G, Al-Mohanna LFA, Jiang L, Öztürk MM, Knobel M, Ivanov P, Petrucelli L, Wegmann S, Kanaan NM, Wolozin B. TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci U S A. 2021 03 02; 118(9).View Related Profiles. PMID: 33619090; PMCID: PMC7936275; DOI: 10.1073/pnas.2014188118;
Song S, Wang Q, Jiang L, Oyarzabal E, Riddick NV, Wilson B, Moy SS, Shih YI, Hong JS. Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. Brain Behav Immun. 2019 10; 81:374-387. PMID: 31247288; PMCID: PMC6754798; DOI: 10.1016/j.bbi.2019.06.034;
Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, Zhang C, Yu WH, Leszyk J, Abisambra JF, Li H, Wolozin B. RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol Commun. 2018 08 01; 6(1):71.View Related Profiles. PMID: 30068389; PMCID: PMC6069705; DOI: 10.1186/s40478-018-0574-5;
Song S, Jiang L, Oyarzabal EA, Wilson B, Li Z, Shih YI, Wang Q, Hong JS. Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration. Mol Neurobiol. 2019 Apr; 56(4):2653-2669. PMID: 30051353; PMCID: PMC6348128; DOI: 10.1007/s12035-018-1235-1;
Wang S, Chu CH, Guo M, Jiang L, Nie H, Zhang W, Wilson B, Yang L, Stewart T, Hong JS, Zhang J. Identification of a specific a-synuclein peptide (a-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. J Neuroinflammation. 2016 06 21; 13(1):158. PMID: 27329107; PMCID: PMC4915166; DOI: 10.1186/s12974-016-0606-7;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.